Osteoporosis Therapy: Bone Modeling during Growth and Aging.
作者信息
Sugiyama Toshihiro, Oda Hiromi
机构信息
Department of Orthopaedic Surgery, Saitama Medical University , Saitama , Japan.
出版信息
Front Endocrinol (Lausanne). 2017 Mar 9;8:46. doi: 10.3389/fendo.2017.00046. eCollection 2017.
Abstract
摘要
相似文献
1
Osteoporosis Therapy: Bone Modeling during Growth and Aging.骨质疏松症治疗：生长与衰老过程中的骨重塑
Front Endocrinol (Lausanne). 2017 Mar 9;8:46. doi: 10.3389/fendo.2017.00046. eCollection 2017.
2
Effects of abaloparatide, a human parathyroid hormone-related peptide analog, on bone mineral density in postmenopausal women with osteoporosis.阿巴洛肽（一种人甲状旁腺激素相关肽类似物）对绝经后骨质疏松症女性骨矿物质密度的影响。
J Clin Endocrinol Metab. 2015 Feb;100(2):697-706. doi: 10.1210/jc.2014-3718. Epub 2014 Nov 13.
3
[Development of osteoporosis drugs -the past, the present and the future-.].[骨质疏松症药物的发展——过去、现在与未来。]
Clin Calcium. 2017;27(1):137-141.
4
Novel therapies for osteoporosis.骨质疏松症的新型疗法。
Metabolism. 2015 Oct;64(10):1199-214. doi: 10.1016/j.metabol.2015.07.011. Epub 2015 Jul 21.
5
Romosozumab and blosozumab: alternative drugs of mechanical strain-related stimulus toward a cure for osteoporosis.罗莫索单抗和布洛索单抗：针对机械应力相关刺激治疗骨质疏松症的替代药物。
Front Endocrinol (Lausanne). 2015 Apr 21;6:54. doi: 10.3389/fendo.2015.00054. eCollection 2015.
6
Emerging drugs for osteoporosis.骨质疏松症的新型药物
Expert Opin Emerg Drugs. 2014 Sep;19(3):385-95. doi: 10.1517/14728214.2014.936377. Epub 2014 Jul 4.
7
The role of changes in mechanical usage set points in the pathogenesis of osteoporosis.机械使用设定点变化在骨质疏松症发病机制中的作用。
J Bone Miner Res. 1992 Mar;7(3):253-61. doi: 10.1002/jbmr.5650070303.
8
[Developments of the theory of skeletal adaptation to mechanical loading].[骨骼对机械负荷适应理论的发展]
Space Med Med Eng (Beijing). 1999 Jun;12(3):226-30.
9
Changes in bone mechanical strength in response to physical therapy.物理治疗对骨力学强度的影响
Pol Arch Med Wewn. 2010 Sep;120(9):368-73.
10
On our age-related bone loss: insights from a new paradigm.关于我们与年龄相关的骨质流失：来自一种新范式的见解。
J Bone Miner Res. 1997 Oct;12(10):1539-46. doi: 10.1359/jbmr.1997.12.10.1539.
引用本文的文献
1
Insights into the Mechanism of Osteoporosis and the Available Treatment Options.骨质疏松症的发病机制及现有治疗选择的研究进展。
Curr Pharm Biotechnol. 2024;25(12):1538-1551. doi: 10.2174/0113892010273783231027073117.
2
Vertebral Body Reshaping after Fractures: An Important Index of Recovery in Glucocorticoid-Treated Children.骨折后椎体重塑：糖皮质激素治疗儿童恢复的一项重要指标。
J Clin Endocrinol Metab. 2024 Feb 20;109(3):e1225-e1237. doi: 10.1210/clinem/dgad611.
3
Roles of sex hormones in mediating the causal effect of vitamin D on osteoporosis: A two-step Mendelian randomization study.性激素在介导维生素 D 对骨质疏松症的因果效应中的作用：两步孟德尔随机化研究。
Front Endocrinol (Lausanne). 2023 Mar 30;14:1159241. doi: 10.3389/fendo.2023.1159241. eCollection 2023.
4
A novel prognostic 6-gene signature for osteoporosis.一种用于骨质疏松症的新型预后 6 基因标志物。
Front Endocrinol (Lausanne). 2022 Sep 21;13:968397. doi: 10.3389/fendo.2022.968397. eCollection 2022.
5
Integrated Bioinformatic Analysis of the Shared Molecular Mechanisms Between Osteoporosis and Atherosclerosis.骨质疏松症与动脉粥样硬化共享分子机制的综合生物信息学分析。
Front Endocrinol (Lausanne). 2022 Jul 22;13:950030. doi: 10.3389/fendo.2022.950030. eCollection 2022.
6
Three-dimensional microstructures of the intracortical canals in the animal model of osteoporosis.骨质疏松动物模型中皮质内微管的三维微观结构。
Anat Cell Biol. 2020 Jun 30;53(2):162-168. doi: 10.5115/acb.19.189.
7
Current and future uses of skeletal stem cells for bone regeneration.骨骼干细胞在骨再生中的当前及未来应用
World J Stem Cells. 2020 May 26;12(5):339-350. doi: 10.4252/wjsc.v12.i5.339.
8
Silk fibroin/hydroxyapatite scaffold: a highly compatible material for bone regeneration.丝素蛋白/羟基磷灰石支架：一种用于骨再生的高度相容性材料。
Sci Technol Adv Mater. 2020 Apr 30;21(1):242-266. doi: 10.1080/14686996.2020.1748520. eCollection 2020.
9
Strategies for optimising musculoskeletal health in the 21 century.21世纪优化肌肉骨骼健康的策略。
BMC Musculoskelet Disord. 2019 Apr 11;20(1):164. doi: 10.1186/s12891-019-2510-7.
本文引用的文献
1
Bone modeling and remodeling: potential as therapeutic targets for the treatment of osteoporosis.骨建模与重塑：作为骨质疏松症治疗靶点的潜力。
Ther Adv Musculoskelet Dis. 2016 Dec;8(6):225-235. doi: 10.1177/1759720X16670154. Epub 2016 Oct 5.
2
Goal-Directed Treatment for Osteoporosis: A Progress Report From the ASBMR-NOF Working Group on Goal-Directed Treatment for Osteoporosis.骨质疏松症的目标导向治疗：美国骨矿研究学会 - 美国国家骨质疏松基金会骨质疏松症目标导向治疗工作组的进展报告
J Bone Miner Res. 2017 Jan;32(1):3-10. doi: 10.1002/jbmr.3039. Epub 2016 Dec 27.
3
Postmenopausal osteoporosis.绝经后骨质疏松症
Nat Rev Dis Primers. 2016 Sep 29;2:16069. doi: 10.1038/nrdp.2016.69.
4
Bone Densitometry in Children and Adolescents.儿童和青少年的骨密度测定
Pediatrics. 2016 Oct;138(4). doi: 10.1542/peds.2016-2398.
5
Romosozumab Treatment in Postmenopausal Women with Osteoporosis.罗莫佐单抗治疗绝经后骨质疏松症妇女。
N Engl J Med. 2016 Oct 20;375(16):1532-1543. doi: 10.1056/NEJMoa1607948. Epub 2016 Sep 18.
6
Carcinogenicity risk assessment of romosozumab: A review of scientific weight-of-evidence and findings in a rat lifetime pharmacology study.罗莫单抗的致癌性风险评估：大鼠终生药理学研究中科学证据权重及结果综述
Regul Toxicol Pharmacol. 2016 Nov;81:212-222. doi: 10.1016/j.yrtph.2016.08.010. Epub 2016 Aug 26.
7
Effect of Abaloparatide vs Placebo on New Vertebral Fractures in Postmenopausal Women With Osteoporosis: A Randomized Clinical Trial.阿巴洛肽与安慰剂对绝经后骨质疏松症妇女新发椎体骨折的影响：一项随机临床试验。
JAMA. 2016 Aug 16;316(7):722-33. doi: 10.1001/jama.2016.11136.
8
Letter to the Editor: Combination Treatment With Teriparatide and Denosumab in Osteoporosis.致编辑的信：特立帕肽与地诺单抗联合治疗骨质疏松症
J Clin Endocrinol Metab. 2016 Aug;101(8):L80-1. doi: 10.1210/jc.2016-2343.
9
Informing evidence-based clinical practice guidelines for children with cerebral palsy at risk of osteoporosis: an update.为有骨质疏松风险的脑瘫患儿制定循证临床实践指南：更新版
Dev Med Child Neurol. 2016 Sep;58(9):918-23. doi: 10.1111/dmcn.13196. Epub 2016 Jul 20.
10
Six Weeks of Daily Abaloparatide Treatment Increased Vertebral and Femoral Bone Mineral Density, Microarchitecture and Strength in Ovariectomized Osteopenic Rats.六周每日阿巴洛肽治疗可增加去卵巢骨质疏松大鼠的椎骨和股骨骨矿物质密度、骨微结构及骨强度。
Calcif Tissue Int. 2016 Nov;99(5):489-499. doi: 10.1007/s00223-016-0171-1. Epub 2016 Jul 9.
Zotero 插件